IBI112 for teens with moderate to severe plaque psoriasis
Part of Skin clinical trials.
This study tests a new medicine called IBI112 for teens aged 12–18 with moderate to severe plaque psoriasis. It aims to see if the medicine is safe and can help clear skin better than placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 18 years old.
- You have had plaque psoriasis for at least 6 months.
- Your psoriasis is severe enough that your doctor has recommended light therapy or systemic (pill/injection) treatment.
- You have not taken a biologic medicine targeting IL-17 in the last 6 months or targeting TNF-alpha in the last 3 months.
- You do not have other forms of psoriasis (like pustular or guttate) or serious uncontrolled health problems.
- You have not used certain psoriasis creams or systemic treatments within specific timeframes before the study starts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication (HS-10374) taken by mouth to see if it is safe and effective for people with moderate to severe plaque psoriasis. It might help reduce the redness, scaling, and thickness of psoriasis plaques.
This trial tests an experimental pill that may help clear psoriasis plaques. It is for people whose current topical treatments (creams or ointments) are not working well enough or cause side effects.
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
This study looks at what’s happening inside the body in people with plaque psoriasis who start certain biologic medicines that target the IL-23/IL-17 immune pathway. It may help explain why these treatments work and what body changes are linked to response.
This study tests a new injection called SHR-1139 for people with moderate-to-severe plaque psoriasis. The goal is to see if it can safely improve your skin condition.
This Phase 1 study tests a new drug (SFA002) in adults with stable plaque psoriasis. It mainly focuses on safety and how the body responds, and may eventually help people with psoriasis plaques.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.